| Date Filed | Type | Description |
| 09/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/28/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 08/23/2023 |
4
| Blume-Jensen Peter (President and CEO) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 493,994 shares
@ $0 |
|
| 08/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, August 11, 2023 - Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the second quarter ended June 30, 2023 and provided business highlights. “The Acrivon team has made significant progress during the second quarter, both on the clinical and preclinical development fronts, as well as with the expansion of our board and executive leadership team with strategic additions,” said Peter Blume-Jensen, ..." |
|
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/28/2023 |
4
| BAUM CHARLES M (Director) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Granted 32,500 options to buy
@ $12.88, valued at
$418.6k
|
|
| 06/28/2023 |
3
| BAUM CHARLES M (Director) has filed a Form 3 on Acrivon Therapeutics, Inc. |
| 06/28/2023 |
4
| Chione Ltd (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Sold 16 shares
@ $12.93, valued at
$206.9 |
|
| 06/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/06/2023 |
4
| Devroe Eric (COO) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Exercised 9,225 options to buy
@ $1.04, valued at
$9.6k
|
|
| 06/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 06/01/2023 |
4
| Blume-Jensen Peter (President and CEO) has filed a Form 4 on Acrivon Therapeutics, Inc.|
Txns:
| Exercised 33,605 options to buy
@ $3.88, valued at
$130.4k
|
|
| 05/30/2023 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
| 05/09/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/01/2023 |
8-K
| Investor presentation |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
8-K
| Investor presentation |
| 02/14/2023 |
SC 13G/A
| Sands Capital Ventures, LLC reports a 7.9% stake in Acrivon Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 14.4% stake in Acrivon Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/15/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/28/2022 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 23.1% stake in ACRIVON THERAPEUTICS, INC. |
| 11/28/2022 |
SC 13G
| Chione Ltd reports a 18.5% stake in Acrivon Therapeutics, Inc. |
| 11/25/2022 |
SC 13G
| Sands Capital Life Sciences Pulse Fund II, L.P. reports a 7.9% stake in Acrivon Therapeutics, Inc. |
|